Candel Therapeutics posts corporate presentation on cancer immunotherapy pipeline led by CAN-2409 and CAN-3110 programs

Candel Therapeutics, Inc.

Candel Therapeutics, Inc.

CADL

0.00
  • Candel Therapeutics outlined late-stage plans for CAN-2409, citing a positive Phase 3 placebo-controlled prostate cancer trial that met disease-free survival.
  • Program positioned for potential BLA readiness in localized intermediate- to high-risk prostate cancer, supported by FDA RMAT designation.
  • Pipeline update highlighted positive overall survival signals in Phase 2a studies of CAN-2409 in borderline resectable pancreatic cancer, therapy-resistant NSCLC.
  • Balance sheet snapshot showed cash and cash equivalents of $194.8 million as of March 31, 2026, projecting runway into Q1 2028.
  • Financing included a Trinity Capital term loan facility of up to $130 million, Royalty funding agreement with RTW Investments for $100 million tied to prostate approval.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief on July 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.